[go: up one dir, main page]

AR033792A1 - Compuestos anti - tumorales activados por paf - Google Patents

Compuestos anti - tumorales activados por paf

Info

Publication number
AR033792A1
AR033792A1 ARP000102287A ARP000102287A AR033792A1 AR 033792 A1 AR033792 A1 AR 033792A1 AR P000102287 A ARP000102287 A AR P000102287A AR P000102287 A ARP000102287 A AR P000102287A AR 033792 A1 AR033792 A1 AR 033792A1
Authority
AR
Argentina
Prior art keywords
paf
compounds activated
pafalfa
prodrug
tumoral compounds
Prior art date
Application number
ARP000102287A
Other languages
English (en)
Inventor
John-Edward Dr Park
Wolfgang J Dr Rettig
Martin Dr Lenter
Stefan Dr Peters
Pilar Dr Garin-Chesa
Juergen Dr Mack
Dietmar Dr Leipert
Raymond A Dr Firestone
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of AR033792A1 publication Critical patent/AR033792A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a un profármaco que es capaz de ser convertido por la acción catalítica de proteína de activación de fibroblastos humana (PAFalfa), teniendo dicho profármaco un sitio de escisión que es reconocido por PAFalfa, y siendo dicho fármaco citotóxico o citostático en condiciones fisiológicas
ARP000102287A 1999-05-14 2000-05-12 Compuestos anti - tumorales activados por paf AR033792A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13413699P 1999-05-14 1999-05-14

Publications (1)

Publication Number Publication Date
AR033792A1 true AR033792A1 (es) 2004-01-07

Family

ID=22461925

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102287A AR033792A1 (es) 1999-05-14 2000-05-12 Compuestos anti - tumorales activados por paf

Country Status (28)

Country Link
US (1) US6613879B1 (es)
EP (1) EP1180116A2 (es)
JP (1) JP3607201B2 (es)
KR (1) KR20020030270A (es)
CN (1) CN1213058C (es)
AR (1) AR033792A1 (es)
AU (1) AU777521B2 (es)
BG (1) BG106096A (es)
BR (1) BR0010564A (es)
CA (1) CA2369933A1 (es)
CO (1) CO5170516A1 (es)
CZ (1) CZ20014097A3 (es)
EA (1) EA005204B1 (es)
EE (1) EE200100600A (es)
HK (1) HK1048642B (es)
HU (1) HUP0202367A3 (es)
IL (1) IL145798A0 (es)
MX (1) MXPA01011401A (es)
MY (1) MY125939A (es)
NO (1) NO20015536L (es)
NZ (1) NZ516075A (es)
PL (1) PL351680A1 (es)
SK (1) SK16452001A3 (es)
TW (1) TWI248444B (es)
UA (1) UA73506C2 (es)
WO (1) WO2000071571A2 (es)
YU (1) YU80901A (es)
ZA (1) ZA200109151B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068145A2 (en) 2000-03-15 2001-09-20 Bristol-Myers Squibb Pharma Company Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
GB0027552D0 (en) * 2000-11-10 2000-12-27 Boehringer Ingelheim Pharma Anti-tumor compounds
GB0027551D0 (en) * 2000-11-10 2000-12-27 Boehringer Ingelheim Pharma Anti-tumor compounds
WO2002089739A2 (en) * 2001-05-09 2002-11-14 Newbiotics, Inc. Peptide deformylase activated prodrugs
US7091186B2 (en) * 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
EP1333033A1 (en) * 2002-01-30 2003-08-06 Boehringer Ingelheim Pharma GmbH & Co.KG FAP-activated anti-tumor compounds
US20030211979A1 (en) * 2002-01-30 2003-11-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg FAP-activated anti-tumor compounds
EP1499318A4 (en) * 2002-04-18 2006-07-19 Celmed Oncology Usa Inc Peptide deformylase activated prodrugs
EP1506221A2 (en) * 2002-05-10 2005-02-16 Boehringer Ingelheim Pharma GmbH & Co.KG Fap-activated anti-tumor prodrugs
US20040033957A1 (en) * 2002-05-10 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg FAP-activated anti-tumor prodrugs
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
JP2006514009A (ja) * 2002-11-14 2006-04-27 セルメド オンコロジー （ユーエスエイ）， インコーポレイテッド ペプチドデホルミラーゼ活性化プロドラッグ
GB0310593D0 (en) 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
EP1625122A1 (en) 2003-05-14 2006-02-15 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006073167A1 (ja) * 2005-01-07 2006-07-13 Ono Pharmaceutical Co., Ltd. ピロリジン誘導体
CA2606785A1 (en) 2005-05-19 2006-11-23 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
EP1963537A4 (en) * 2005-12-14 2009-11-11 Ludwig Inst For Cancer Res Ltd METHOD FOR DIAGNOSING RHEUMATOID ARTHRITIS BY TESTING MYOFIBROBLASTIC-SIMILAR SYNOVOCYTES FOR A FIBROBLAST ACTIVATION PROTEIN
WO2007087131A2 (en) * 2006-01-05 2007-08-02 The Johns Hopkins University Peptide prodrugs
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2008005479A2 (en) * 2006-07-06 2008-01-10 University Of Wyoming Charge reversible polymers
WO2008116053A2 (en) * 2007-03-20 2008-09-25 Trustees Of Tufts College Fap-activated chemotherapeutic compounds, and methods of use thereof
JP5781930B2 (ja) * 2008-09-12 2015-09-24 カディラ ファーマシューティカルズ リミテッド 新規なジペプチジルペプチダーゼ（ｄｐ−ｉｖ）化合物
DK2525830T3 (en) 2010-01-22 2016-08-15 Ascendis Pharma As DIPEPTID-BASED PRODRUG LINKERS TO ALIFATIC AMINE-CONTAINING MEDICINES
US20130030359A1 (en) 2010-01-22 2013-01-31 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
US20150335761A1 (en) * 2012-02-16 2015-11-26 Raymond Firestone Compositions and methods for contraception
AU2013369261B2 (en) 2012-12-28 2018-08-09 Cobiores Nv Minimally toxic prodrugs
WO2014169697A1 (zh) * 2013-04-19 2014-10-23 暨南大学 长春碱类衍生物及其制备方法和应用
EP3564234B1 (en) * 2013-11-05 2021-09-29 AstraZeneca AB Nmda antagonist prodrugs
US9737556B2 (en) * 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto
HUE063194T2 (hu) * 2014-06-13 2024-01-28 Bach Biosciences Llc FAP-aktivált terápiás szerek és az azokkal kapcsolatos felhasználások
CN105524141B (zh) * 2015-11-12 2019-11-26 中山大学 一种FAPa激活式肿瘤诊断多肽磁珠复合物的制备与应用
EP3222292A1 (en) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
CN107043456B (zh) * 2017-04-19 2019-05-17 川北医学院 对氧环己酮与l-苯丙氨酸氮芥共聚物及其应用
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
CN110128501A (zh) * 2019-05-21 2019-08-16 北京海美源医药科技有限公司 一种靶向fap酶的喜树碱类化合物及其制备方法和应用
CN110128506B (zh) * 2019-05-22 2021-03-30 中国药科大学 一种寡肽及其应用
WO2025200088A1 (zh) * 2024-03-27 2025-10-02 广州医科大学 靶向kras的多肽与小分子的偶联物及其抗癌应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3915800A (en) * 1972-03-30 1975-10-28 Kelco Co Polysaccharide and bacterial fermentation process for its preparation
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
US5047401A (en) * 1985-09-09 1991-09-10 Board Of Regents, The University Of Texas System Use of dipeptide alkyl esters to treat GVHD
ES2053547T3 (es) 1986-07-29 1994-08-01 Sunstar Kk Reactivo para someter a ensayo enfermedades periodontales.
US5776892A (en) * 1990-12-21 1998-07-07 Curative Health Services, Inc. Anti-inflammatory peptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
DE19512484A1 (de) * 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
EP0855910A4 (en) 1995-10-18 2000-07-05 Merck & Co Inc Conjugates that can be used to treat benign prostate hyperplasia
CA2256669A1 (en) 1996-05-29 1997-12-04 Prototek, Inc. Prodrugs of thalidomide and methods for using same as modulators of t-cell function
US5952294A (en) 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
DE19640970A1 (de) * 1996-10-04 1998-04-16 Bayer Ag Modifizierte Cytostatika
DE69942128D1 (de) 1998-12-11 2010-04-22 Coulter Pharm Inc Prodrugs und verfahren zu deren herstellung
EP1176985A2 (en) 1999-04-28 2002-02-06 Vectramed, Inc. Enzymatically activated polymeric drug conjugates

Also Published As

Publication number Publication date
CO5170516A1 (es) 2002-06-27
EP1180116A2 (en) 2002-02-20
IL145798A0 (en) 2002-07-25
UA73506C2 (en) 2005-08-15
TWI248444B (en) 2006-02-01
JP3607201B2 (ja) 2005-01-05
NO20015536D0 (no) 2001-11-13
AU6559100A (en) 2000-12-12
CA2369933A1 (en) 2000-11-30
CN1374969A (zh) 2002-10-16
ZA200109151B (en) 2002-12-17
NZ516075A (en) 2004-03-26
EA200101155A1 (ru) 2002-10-31
EE200100600A (et) 2003-02-17
AU777521B2 (en) 2004-10-21
WO2000071571A3 (en) 2001-09-07
EA005204B1 (ru) 2004-12-30
SK16452001A3 (sk) 2002-03-05
KR20020030270A (ko) 2002-04-24
HK1048642A1 (en) 2003-04-11
HUP0202367A2 (hu) 2002-11-28
US6613879B1 (en) 2003-09-02
MY125939A (en) 2006-09-29
CN1213058C (zh) 2005-08-03
HK1048642B (zh) 2005-10-28
JP2003500417A (ja) 2003-01-07
MXPA01011401A (es) 2002-06-04
NO20015536L (no) 2002-01-10
WO2000071571A8 (en) 2002-03-07
HUP0202367A3 (en) 2003-10-28
WO2000071571A2 (en) 2000-11-30
YU80901A (sh) 2005-07-19
BG106096A (bg) 2002-05-31
PL351680A1 (en) 2003-06-02
CZ20014097A3 (cs) 2002-02-13
BR0010564A (pt) 2002-02-19

Similar Documents

Publication Publication Date Title
AR033792A1 (es) Compuestos anti - tumorales activados por paf
CY1114420T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση που περιλαμβανει καλσιποτριολη και βηταμεθαζονη για την αγωγη της ψωριασης
CY1112753T1 (el) Θεραπευτικη αγωγη καρκινων του ανθρωπινου σωματος με τη χρηση toy ετ743
IL199914B (en) Use of protein kinase n beta for the manufacture of a diagnostic agent
HN1999000080A (es) Derivados de isotiazol utiles como agentes anticancerosos.
AR025444A1 (es) Derivados de sulfonil-carboxamida, procedimientos para su preparacion y su utilizacion como medicamentos
ATE336255T1 (de) Hyaluronsäure-ester zur behandlung von normotrophischen hautnarben
PA8487201A1 (es) Moduladores de ccr5
HRP20040758B1 (hr) Uporaba il-18 inhibitora za lijeäśenje i/ili prevenciju perifernih krvožilnih bolesti
DOP2002000429A (es) Imidazotriazinas
CY1110078T1 (el) Παρασκευασματα με ιωδιουχο ποβιδονη για την αγωγη τραυματων
CY1113894T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει ροφλουμιλαστη και λεβοκετιριζινη
HUP9800938A2 (hu) NK-1 receptor antagonisták alkalmazása irritációs bélszindróma tüneteinek kezelésére
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
DE60115054D1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
UY27014A1 (es) Compuestos antitumorales activados por fap ii
BR9812531A (pt) Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica
UY26140A1 (es) Compuesto anti-tumorales activados por paf.
PA8531601A1 (es) Nuevos heteroaromatos
BR0013723A (pt) Uso de bissulfonamidas, para produção de medicamentos para profilaxia ou tratamento de hiperlipidemia
ATE331730T1 (de) Neue depsipeptid-verbindung
HN2001000204A (es) Amidas de acido fenilciclohexanocarboxilico sustituido y su uso
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
BR0104005A (pt) Composição farmacêutica para a prevenção ou para o tratamento de uma doença associada com um excesso de produção de il-2
SV2002000639A (es) Alcanosulfonatos de fenoxifenilo ref. lea 34813-sv

Legal Events

Date Code Title Description
FB Suspension of granting procedure